APPLICATION OF METHYLENE BLUE IN THE TREATMENT OF COVID-19

Authors

Vadim Chursin
Kazakh Medical University of Continuing Education, Department of Anesthesiology and Reanimatology with a course of transfusiology. Almaty, Kazakhstan
Ardak Arynov
Kazakh Medical University of Continuing Education, Department of Anesthesiology and Reanimatology with a course of transfusiology. Almaty, Kazakhstan

Synopsis

A solution of methylene blue (MB) has a proven efficacy against the SARS-CoV-2 virus in vitro and is used to inactivate blood components. When used in patients with proven or suspected coronavirus infection at the initial stage of the disease, MB has shown clinical and laboratory efficacy as an etiotropic drug. When used in patients with already severe lung damage, the effectiveness of MB was not noted. Taking into account the absence of side effects, MB can be recommended for etiotropic therapy for COVID-19 in the early stages of the disease in the off-label mode.

PANDEMIC–ICT–2020
Publication
Abstracts of the First Eurasian Conference; The Coronavirus Pandemic and Critical ICT Infrastructure
PDF
Published
December 24, 2020
Series
AIJR Abstracts
Copyright (c) 2020 held by the author(s) of the individual abstract
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.